Trial Profile
Emergency Use Protocol for EPI-743 in Acutely Ill Patients With Inherited Mitochondrial Respiratory Chain Disease Within 90 Days of End-of-Life Care
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Vatiquinone (Primary)
- Indications Mitochondrial disorders
- Focus Adverse reactions; Expanded access
- Sponsors PTC Therapeutics
- 19 Jan 2024 This Trial is now an Expanded Access study.
- 10 Oct 2023 Status changed from active, no longer recruiting to completed.
- 12 Sep 2023 Planned End Date changed from 31 Aug 2023 to 31 Oct 2023.